CAMBRIDGE, Mass., July 14, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer ...
Blueprint Medicines Corporation BPMC announced that it has entered into a global collaboration agreement with Genentech, a subsidiary of Roche RHHBY, to develop/commercialize the precision therapy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback